Antoine Azar, MD
Allergy & Immunology · Baltimore, MDNPI 1811029242
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Grifols USA, LLC at 35.0% of the total. Among allergy & immunology clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 663 payments — averaging $922.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Grifols USA, LLC$214K
- Takeda Pharmaceuticals U.S.A., Inc.$152K
- Argenx US, Inc.$66K
- ADMA Biomanufacturing LLC$61K
- CSL Behring$40K
- Grifols Shared Services North America, Inc.$18K
- plus $61K from 19 others
Across 49 payments — averaging $7852.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- X4 Pharmaceuticals, Inc.$215K
- Grifols Shared Services North America, Inc.$93K
- Octapharma USA, Inc.$48K
- CSL Behring$13K
- Roche Products Limited$10K
- Novartis$5K
What the payments were for
- Consulting fees$187,70031%
- Speaking & faculty fees$329,96554%
- Travel & lodging$75,28512%
- Food & beverage$18,5793%
- Education$2760%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Grifols USA, LLC | 281 | $214,073 |
| Takeda Pharmaceuticals U.S.A., Inc. | 148 | $151,893 |
| Argenx US, Inc. | 21 | $65,952 |
| ADMA Biomanufacturing LLC | 80 | $61,285 |
| CSL Behring | 30 | $40,012 |
| Grifols Shared Services North America, Inc. | 23 | $17,578 |
| Optinose US, Inc. | 12 | $12,641 |
| Sanofi | 13 | $7,981 |
| Amgen(2 entities) | 11 | $7,238 |
| Novartis | 8 | $7,090 |
| GC Biopharma USA, Inc. | 1 | $6,600 |
| X4 Pharmaceuticals, Inc. | 2 | $5,828 |
| Pfizer | 5 | $4,088 |
| Catalyst Pharmaceuticals, Inc. | 7 | $3,701 |
| Pharming Healthcare, Inc. | 5 | $2,774 |
| Invivyd Inc | 1 | $2,135 |
| Cook Medical LLC | 4 | $260 |
| GSK | 3 | $183 |
| Circassia Inc. | 1 | $97 |
| Regeneron Healthcare Solutions, Inc. | 1 | $95 |
| AbbVie | 1 | $86 |
| Sanofi-aventis U.S. LLC | 1 | $68 |
| Sobi, Inc | 1 | $63 |
| Octapharma USA, Inc. | 2 | $59 |
| Dermavant Sciences, Inc. | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$611,805 in reported general payments places this provider in the 95th percentile of 105 allergy & immunology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XembifyImmune Globulin,gamma(Igg)klhw | 13 | $268,027 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 12 | $54,745 |
| XhanceFluticasone Propionate | 13 | $14,962 |
| Azelastine Hcl | 21 | $1,091 |
| Ipratropium Bromide | 12 | $693 |
| Montelukast Sodium | 12 | $264 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 11 | $188 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCXembify | $214,073 | $268,02713 claims |
| CSL BehringPrivigen | $40,012 | $54,74512 claims |
| Optinose US, Inc.Xhance | $12,641 | $14,96213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 105 allergy & immunology providers in Maryland.
Other allergy & immunology in Baltimore
- Sally BaileyBaltimore$344K
- Eric OliverBaltimore$31K
- Melanie DispenzaBaltimore$20K
- Monika KorffBaltimore$5K
- Darya KoenigBaltimore$4K
- William LavietesBaltimore$1K
- Mark ScarupaWheaton$508K
- Manav SinglaWhite Marsh$168K
- Sudhir SekhsariaRockville$87K
- Nasim ReedyGaithersburg$63K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.